Prostate Artery Embolization for the Treatment of Benign Prostatic Hyperplasia

John D Louie

Status

Withdrawn

Conditions

Prostatic Hyperplasia

Treatments

Device: Prostate Embolization

Study type

Interventional

Funder types

Other

Identifiers

NCT03179228

PAE-01

Details and patient eligibility

About

The primary study objective is to evaluate improvement of symptoms from benign prostatic hyperplasia (BPH) as assessed by the International Prostate Symptom Score (IPSS) at 12 months post prostatic artery embolization (PAE) with bland microspheres.

Full description

This is a phase II, single center, prospective, single arm, investigational study to evaluate the safety and efficacy of prostate artery embolization (PAE) for treatment of severe lower urinary tract symptoms (LUTS) related to BPH in patients with prostate size greater than 40 grams that either refuse surgical treatment or are considered poor candidates for traditional surgical therapy. Two hundred patients will be enrolled in the single treatment arm with follow-up for no less than 12 months.

The study will involve a screening period in which patient eligibility will be determined. Once eligibility is confirmed, patients will receive PAE with bland microspheres within 4 weeks of screening baseline imaging. After treatment, patients will return for follow-up visits at 1 month, 3 months, 6 months, and 12 months post PAE. At each of these visits, patients will complete IPSS and IIEF questionnaires, undergo a physical exam, laboratory assessment (including PSA) and perform a medication review. Repeat TRUS and uroflowmetry will be performed at the 3, 6, and 12 month post PAE follow-up visits. MRI or CT will be conducted at the 3 and 12 month visit. Cystoscopy and proctoscopy will be performed if medically indicated.

The primary endpoint will be improvement of BPH symptoms as assessed by the IPSS at 12 months post PAE. Patients will continue to be followed according to the institutional standard of care follow-up schedule after they complete the study.

Safety will be evaluated throughout the initial 12 months of the study by assessing adverse events and findings on physical examination. Concomitant medication usage will be assessed.

Sex

Male

Ages

50+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Patient is aged 50 years or older.
Patient has signed informed consent
Patient has experienced lower urinary tract symptoms (LUTS) for at least 6 months prior to study enrollment
Patient has a prostate size larger than 40g as measured by MRI or CT (if MR not possible)
Patient has an IPSS score greater than or equal to 13
Patient either:

i. Refuses surgical treatment ii. Is considered high risk for surgical treatment
Patient is either:

i. Refractory to medical treatment ii. Contraindicated for medical treatment
Patient must meet ONE of the following criteria:
- Baseline PSA ≤ 2.5ng/mL
- Baseline PSA > 2.5 ng/mL and ≤ 10 ng/mL AND free PSA ≥ 25% of total PSA (no biopsy required)
- Baseline PSA > 2.5 ng/mL and ≤ 10 ng/mL AND free PSA < 25% of total PSA AND negative prostate biopsy result (minimum of 12 core biopsy) within 12 months
- Baseline PSA >10 ng/mL AND negative prostate biopsy result (minimum of 12 core biopsy) within 12 months
Patient has a peak urine flow rate < 12ml/sec.

Exclusion criteria

Active prostatitis or urinary tract infection
History of prostate or bladder cancer, or currently being evaluated for cancer
Bladder atonia, neurogenic bladder disorder or other neurological disorder that is impacting bladder function.
Urethral stricture, bladder neck contracture, other potentially confounding bladder pathology, bladder disease, or confounding urethral pathology
Patient has taken beta blockers, antihistamines, anticonvulsants, or antispasomodics within 1 week of study treatment AND has not been on the same drug dosage for 6 months with a stable voiding pattern.
Patient has taken antidepressant, anticholinergics, androgens or gonadotropin-releasing hormonal analogues within 2 months of study treatment AND has not been on the same drug dosage for at least 3 months with a stable voiding pattern.
Patient has taken alpha blockers within 4 weeks of study treatment AND has not been on the same drug dosage for at least 3 months with a stable voiding pattern.
Patient has taken 5-alpha reductase inhibitors within 3 months of study treatment AND has not been on the same drug for at least 6 months with a stable voiding pattern
History of open prostate surgery, radiofrequency, or microwave therapy
Previous open bladder or rectosigmoid colon surgery
Acute urinary retention requiring an indwelling catheter
Cystolithiasis within the past 3 months
Coagulation disturbances not normalized by medical treatment
Iodinated contrast allergy not controlled with 24-hour steroid preparation
History of pelvic irradiation
History of severe peripheral vascular disease or known major iliac arterial occlusive disease
Interest in future fertility
Significant cardiac or respiratory disease that the Investigator believes puts the patient at risk for a complication during the procedure
Acute urinary retention requiring an indwelling catheter
Life expectancy less than 6 months
History of rectal disease
Known immunosuppression either pathological or pharmacological
Presence of collateral vessel pathways potentially endangering normal anatomy during embolization that cannot be bypassed with the microcatheter
History of any illness or surgery that might confound the results of the study, by producing symptoms which may be confused with those of the disease process under consideration (e.g., Parkinson's, multiple Sclerosis), or which pose an additional risk to the patient.